Altium Capital Management LLC Sells 44,648 Shares of Bicycle Therapeutics plc (NASDAQ:BCYC)

Altium Capital Management LLC decreased its position in Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) by 52.5% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 40,352 shares of the company's stock after selling 44,648 shares during the period. Altium Capital Management LLC owned approximately 0.06% of Bicycle Therapeutics worth $565,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in BCYC. State Street Corp increased its holdings in shares of Bicycle Therapeutics by 233.5% in the third quarter. State Street Corp now owns 86,271 shares of the company's stock worth $1,952,000 after acquiring an additional 60,399 shares in the last quarter. Jane Street Group LLC increased its stake in Bicycle Therapeutics by 35.7% during the 3rd quarter. Jane Street Group LLC now owns 20,180 shares of the company's stock worth $457,000 after purchasing an additional 5,310 shares in the last quarter. Geode Capital Management LLC lifted its stake in Bicycle Therapeutics by 79.3% in the third quarter. Geode Capital Management LLC now owns 38,335 shares of the company's stock valued at $868,000 after buying an additional 16,958 shares in the last quarter. Principal Financial Group Inc. bought a new position in Bicycle Therapeutics in the third quarter valued at approximately $10,028,000. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Bicycle Therapeutics by 26.8% in the third quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company's stock valued at $191,000 after buying an additional 1,782 shares during the period. Institutional investors own 86.15% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on BCYC. Stephens reiterated an "equal weight" rating and set a $15.00 target price on shares of Bicycle Therapeutics in a report on Wednesday, January 22nd. HC Wainwright reaffirmed a "buy" rating and set a $33.00 price target on shares of Bicycle Therapeutics in a research report on Wednesday, February 26th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $30.00 price objective on shares of Bicycle Therapeutics in a research report on Wednesday, April 9th. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $29.14.

Bicycle Therapeutics Stock Up 2.1 %

Shares of NASDAQ:BCYC traded up $0.18 during midday trading on Wednesday, hitting $8.91. The stock had a trading volume of 291,811 shares, compared to its average volume of 394,967. The business's 50-day simple moving average is $9.23 and its 200-day simple moving average is $15.32. Bicycle Therapeutics plc has a 12 month low of $6.10 and a 12 month high of $28.67. The company has a market cap of $616.59 million, a P/E ratio of -2.71 and a beta of 1.40.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported ($0.75) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.85) by $0.10. The company had revenue of $3.70 million for the quarter, compared to analysts' expectations of $5.47 million. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. Bicycle Therapeutics's quarterly revenue was down 30.2% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.16) EPS. As a group, equities analysts predict that Bicycle Therapeutics plc will post -3.06 earnings per share for the current year.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.